Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study

References

• World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections. 2021 Jul 15 [accessed 2022 Aug 31]. https://www.who.int/publications/i/item/9789240027077.
   Google Scholar
• Ozer A, Yakupogullari Y, Beytur A, Beytur L, Koroglu M, Salman F, Aydogan F. Risk factors for hepatitis B virus infection in Turkey: a population-based, case-control study. Hepat Mon. 2011;11:1–7.
   PubMed Web of Science ®Google Scholar
• United States Renal Data System. 2019 USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD); 2018.
   Google Scholar
• Kramer A, Pippias M, Noordzij M, Stel VS, Afentakis N, Ambühl PM, Andrusev AM, Fuster EA, Arribas Monzón FE, Åsberg A, et al. The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) registry annual report 2015: a summary. Clin Kidney J. 2018;11(1):108–22. doi:10.1093/ckj/sfx149.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50(RR–5):1–43.
   Google Scholar
• Johnson DW, Fleming SJ. The use of vaccines in renal failure. Clin Pharmacokinet. 1992;22(6):434–46. doi:10.2165/00003088-199222060-00003.
   PubMed Web of Science ®Google Scholar
• Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs. 2003;63:1021–51. doi:10.2165/00003495-200363100-00006.
   PubMed Web of Science ®Google Scholar
• Engerix-B® (hepatitis B vaccine [recombinant]). GlaxoSmithKline. Prescribing Information; 2019.
   Google Scholar
• Tong NKC, Beran J, Kee SA, Miguel JL, Sánchez C, Bayas JM, Vilella A, de Juanes JR, Arrazola P, Calbo-Torrecillas FC, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005;68(5):2298–303. doi:10.1111/j.1523-1755.2005.00689.x.
   PubMed Web of Science ®Google Scholar
• Merck Sharp and Dohme Limited. HBVAXPRO 40 mcg. Summary of Product Characteristics. 2019. London, UK: Merck Sharp & Dohme UK Ltd.
   Google Scholar
• Girndt M, Litjens NH. Unmet needs and new promises in hepatitis B vaccination for chronic kidney disease patients. Eur Nephrol. 2010;4:14–18.
   Google Scholar
• Centers for Disease Control and Prevention. Protection against viral hepatitis. Recommendations of the immunization practices advisory committee (ACIP). MMWR Morbid Mortal Wkly Rep. 1990;39(RR–2):1–26.
   PubMedGoogle Scholar
• Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis. 1999;179(2):489–92. doi:10.1086/314578.
   PubMed Web of Science ®Google Scholar
• Buti M, Viladomiu L, Jardi R, Olmos A, Rodriguez JA, Bartolome J, Esteban R, Guardia J. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol. 1992;12(3):144–47. doi:10.1159/000168436.
   PubMed Web of Science ®Google Scholar
• Mahoney FJ, Kane MA. Hepatitis B vaccine. In: S P, Orenstein W, editors. Vaccines. Philadelphia: W.B. Sauders Company; 1999. p. 158–82.
   Google Scholar
• Chaves SS, Daniels D, Cooper BW, Malo-Schlegel S, Macarthur S, Robbins KC, Kobetitsch JF, McDaniel A, D’Avella JF, Alter MJ. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. Vaccine. 2011;29(52):9618–23. doi:10.1016/j.vaccine.2011.10.057.
   PubMed Web of Science ®Google Scholar
• HEPLISAV-B (hepatitis B vaccine [recombinant], adjuvanted). Dynavax Technologies Corporation. Prescribing Information; 2017.
   Google Scholar
• Fendrix® Summary of product characteristics. GlaxoSmithKline; 2018.
   Google Scholar
• Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–13. doi:10.1093/biomet/26.4.404.
   Google Scholar
• Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine. 2013;31(46):5306–13. doi:10.1016/j.vaccine.2013.05.067.
   PubMed Web of Science ®Google Scholar
• Litjens NH, Huisman M, van den Dorpel M, Betjes MG. Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients. J Am Soc Nephrol. 2008;19:1483–90. doi:10.1681/ASN.2007090971.
   PubMed Web of Science ®Google Scholar
• Janus N, Vacher LV, Karie S, Ledneva E, Deray G. Vaccination and chronic kidney disease. Nephrol Dial Transplant. 2008;23(3):800–07. doi:10.1093/ndt/gfm851.
   PubMed Web of Science ®Google Scholar
• Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999;33(2):356–60. doi:10.1016/S0272-6386(99)70312-4.
   PubMed Web of Science ®Google Scholar
• Fisman DN, Agrawal D, Leder K. Effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis. 2002;35(11):1368–75. doi:10.1086/344271.
   PubMed Web of Science ®Google Scholar
• Winter AP, Follett EAC, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine. 1994;12(9):771–72. doi:10.1016/0264-410X(94)90283-6.
   PubMed Web of Science ®Google Scholar